The Price Shock
Starting September 1, 2025, the private list price of Mounjaro (tirzepatide) in the UK jumped significantly:
Risks from the Price Hike
The increase puts financial pressure on privately paying patients, many of whom fear being priced out. Concerns are rising about:
- Bulk buying or stockpiling, which can worsen shortages.
- Turning to unregulated sources or counterfeit sellers, potentially endangering health.
Health authorities are urging individuals to avoid black-market options and consult verified providers.
Jood’s Price Lock Approach
Amid this turmoil, Jood stands out for its patient-focused response:
- Jood has introduced fixed, locked-in pricing for Mounjaro, protecting customers from any surprise hikes- even as the market price climbs.
- They offer trusted medications (like Mounjaro and Wegovy) under transparent, predictable costs and a simplified switching process.
This strategy contrasts sharply with many providers who are already passing on higher costs or prompting panic stockpiling.
Why Jood’s Model Matters
- Reliability: Patients can budget and plan without worrying about future spikes.
- Continuity of Care: By locking prices, they’re helping ensure uninterrupted treatment- more critical than ever when options are limited.
- Ethical Positioning: Instead of capitalising on price hikes, Jood focuses on maintainable access.
What makes us different
| Issue | Market Reaction | Jood’s Approach |
|---|---|---|
| Price hikes (up to 170%) | Patients risk being priced out | Offers locked prices to shield from increases |
| Risk of sourcing unsafe supplies | Patients may turn to dangerous alternatives | Provides trusted, regulated access |
| Budget unpredictability | Private patients face uncertainty | Delivers transparent pricing for peace of mind |
Customer’s who switched to Jood
Amira’s story
Amira, 38, has been using Mounjaro privately for six months to manage type 2 diabetes and weight loss. For her, the medication has been transformative- improving her blood sugar control and boosting her energy. But when she heard about the September price rise, panic set in.
“I thought I’d have to stop. There’s no way I could justify over £300 a month on one prescription. It felt like all my progress was about to be undone.”
James’ story
James, 44, started Mounjaro earlier this year after struggling with his weight for more than a decade. He describes it as “the first thing that’s ever worked.” The thought of the price increase left him worried about falling back into unhealthy patterns.
“I didn’t want to risk cheap, unsafe versions online- but I also couldn’t pay triple the price. It felt like I was stuck with no good options.”
By offering price stability in a volatile environment, Jood not only safeguards wallets but also ensures that people continue receiving a medication they rely on without stress or compromise.
